[HTML][HTML] Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
AE Frost, RJ Barst, MM Hoeper, HJ Chang… - The Journal of Heart and …, 2015 - Elsevier
Background Imatinib is an oral inhibitor of several protein kinases implicated in the
pathophysiology of pulmonary hypertension. Treatment with imatinib resulted in improved
hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571] in Pulmonary
Arterial Hypertension, a Randomized Efficacy Study [IMPRES]), among pulmonary arterial
hypertension (PAH) patients inadequately responsive to 2 to 3 PAH-specific therapies.
Methods The long-term (up to 204 weeks) safety and efficacy of imatinib in this open-label …
pathophysiology of pulmonary hypertension. Treatment with imatinib resulted in improved
hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571] in Pulmonary
Arterial Hypertension, a Randomized Efficacy Study [IMPRES]), among pulmonary arterial
hypertension (PAH) patients inadequately responsive to 2 to 3 PAH-specific therapies.
Methods The long-term (up to 204 weeks) safety and efficacy of imatinib in this open-label …